CU20120141A7 - Proceso in vitro para la determinación rápida de un estado del paciente con relación a la infección con micobacterium tuberculosis - Google Patents

Proceso in vitro para la determinación rápida de un estado del paciente con relación a la infección con micobacterium tuberculosis

Info

Publication number
CU20120141A7
CU20120141A7 CU2012000141A CU20120141A CU20120141A7 CU 20120141 A7 CU20120141 A7 CU 20120141A7 CU 2012000141 A CU2012000141 A CU 2012000141A CU 20120141 A CU20120141 A CU 20120141A CU 20120141 A7 CU20120141 A7 CU 20120141A7
Authority
CU
Cuba
Prior art keywords
hours
infection
ganma
tuberculosis
cells
Prior art date
Application number
CU2012000141A
Other languages
English (en)
Spanish (es)
Inventor
Ferdinand Hermann Bahlmann
Danilo Fliser
Martina Sester
Urban Sester
Original Assignee
Red Flag Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Flag Diagnostics Gmbh filed Critical Red Flag Diagnostics Gmbh
Publication of CU20120141A7 publication Critical patent/CU20120141A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CU2012000141A 2010-03-19 2012-09-19 Proceso in vitro para la determinación rápida de un estado del paciente con relación a la infección con micobacterium tuberculosis CU20120141A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10157086 2010-03-19
PCT/EP2011/054207 WO2011113953A1 (fr) 2010-03-19 2011-03-21 Procédé in vitro pour la détermination rapide de l'état d'un patient lié à l'infection par mycobacterium tuberculosis

Publications (1)

Publication Number Publication Date
CU20120141A7 true CU20120141A7 (es) 2013-01-30

Family

ID=42457988

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000141A CU20120141A7 (es) 2010-03-19 2012-09-19 Proceso in vitro para la determinación rápida de un estado del paciente con relación a la infección con micobacterium tuberculosis

Country Status (16)

Country Link
US (2) US20130122523A1 (fr)
EP (1) EP2548019A1 (fr)
JP (1) JP5925184B2 (fr)
KR (1) KR20130029063A (fr)
AU (1) AU2011228996B2 (fr)
BR (1) BR112012023678A2 (fr)
CA (1) CA2793151C (fr)
CL (1) CL2012002542A1 (fr)
CO (1) CO6640286A2 (fr)
CU (1) CU20120141A7 (fr)
MD (1) MD20120084A2 (fr)
MX (1) MX2012010720A (fr)
RU (1) RU2012144417A (fr)
SG (1) SG184103A1 (fr)
WO (1) WO2011113953A1 (fr)
ZA (1) ZA201206950B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860056A1 (fr) 2010-12-23 2012-06-28 Centre Hospitalier Universitaire Vaudois Procedes de differenciation entre des etats pathologiques
WO2012167307A1 (fr) * 2011-06-06 2012-12-13 The University Of Melbourne Diagnostic d'infection par mycobactéries
WO2013106338A1 (fr) 2012-01-12 2013-07-18 Mayo Foundation For Medical Education And Research Détection d'infections tuberculeuses latentes
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
JP6306124B2 (ja) * 2016-11-01 2018-04-04 国立大学法人高知大学 結核検査用バイオマーカー
EP3555630B1 (fr) 2016-12-14 2023-05-31 Becton, Dickinson and Company Procédés et compositions permettant d'obtenir une évaluation de la tuberculose chez un sujet
CN107831316A (zh) * 2017-10-31 2018-03-23 扬州大学 一种用于诊断牛结核病的流式细胞术检测试剂盒
CN109777852A (zh) * 2019-01-29 2019-05-21 浙江省人民医院 特异性抗原刺激cd4淋巴细胞表达cd69用于诊断结核杆菌感染的方法
KR102326294B1 (ko) * 2019-10-27 2021-11-16 바디텍메드(주) 결핵 진단 장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
AU2002219338B2 (en) * 2001-01-08 2006-12-14 Oxford Immunotec Limited Assay to determine efficacy of treatment for mycobacterial infection
CN101094795A (zh) * 2004-12-30 2007-12-26 药物混合系统股份公司 用于液体和粉末材料的多组分分发设备
WO2006072787A1 (fr) * 2005-01-05 2006-07-13 Isis Innovation Limited Compositions permettant d'immuniser contre mycobacterium
EP1767937A1 (fr) * 2005-09-27 2007-03-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé de diagnostic du syndrome de restauration immunitaire (IRS) lié à la tuberculose
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
EP2132569B1 (fr) 2007-03-16 2015-10-28 Cellestis Limited Analyse de réponse immunitaire à médiation cellulaire et kits destinés à cette analyse

Also Published As

Publication number Publication date
RU2012144417A (ru) 2014-04-27
EP2548019A1 (fr) 2013-01-23
JP5925184B2 (ja) 2016-05-25
JP2013522637A (ja) 2013-06-13
AU2011228996A1 (en) 2012-10-11
ZA201206950B (en) 2013-05-29
US20130122523A1 (en) 2013-05-16
CA2793151A1 (fr) 2011-09-22
US9476877B2 (en) 2016-10-25
US20150099652A1 (en) 2015-04-09
SG184103A1 (en) 2012-10-30
AU2011228996B2 (en) 2015-01-29
CO6640286A2 (es) 2013-03-22
CA2793151C (fr) 2018-05-22
MD20120084A2 (ro) 2013-04-30
KR20130029063A (ko) 2013-03-21
MX2012010720A (es) 2013-01-29
WO2011113953A1 (fr) 2011-09-22
BR112012023678A2 (pt) 2016-08-23
CL2012002542A1 (es) 2013-02-08

Similar Documents

Publication Publication Date Title
CU20120141A7 (es) Proceso in vitro para la determinación rápida de un estado del paciente con relación a la infección con micobacterium tuberculosis
Yang et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction
He et al. Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development
Chng et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare
Cohen et al. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy
Silva et al. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells
De Francesco et al. Bacterial species present in the lower male genital tract: a five-year retrospective study
Mohammadnia-Afrouzi et al. Altered microRNA expression and immunosuppressive cytokine production by regulatory T cells of ulcerative colitis patients
Silva et al. Human naive regulatory T-cells feature high steady-state turnover and are maintained by IL-7
EA201370070A1 (ru) СПОСОБ ДЕТЕКЦИИ, ДИФФЕРЕНЦИАЦИИ И КВАНТИФИКАЦИИ ПОПУЛЯЦИЙ Т-КЛЕТОК С ИСПОЛЬЗОВАНИЕМ КОЛИЧЕСТВЕННОЙ ПЦР С ОБРАТНОЙ ТРАНСКРИПЦИЕЙ В РЕАЛЬНОМ ВРЕМЕНИ (ОТ-колПЦР РВ)
Terrazzano et al. Type 1 diabetes progression is associated with loss of CD3+ CD56+ regulatory T cells that control CD8+ T-cell effector functions
Cai et al. Adoptively transferred donor IL-17-producing CD4+ T cells augment, but IL-17 alleviates, acute graft-versus-host disease
Eleftheriadis et al. The indoleamine 2, 3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes
SG170051A1 (en) T cell assays
Oliveria et al. Regulatory and IgE+ B cells in allergic asthma
Xing et al. Expansion of polymorphonuclear myeloid-derived suppressor cells in patients with end-stage renal disease may lead to infectious complications
Guo et al. Stability and inhibitory function of Treg cells under inflammatory conditions in vitro
Li et al. NAMPT is a metabolic checkpoint of IFNγ-producing CD4+ T cells in lupus nephritis
Moreira et al. Histone deacetylase-2 controls IL-1β production through the regulation of NLRP3 expression and activation in tuberculosis infection
Bamidele et al. Interleukin 21 Drives a Hypermetabolic State and CD4+ T-Cell–Associated Pathogenicity in Chronic Intestinal Inflammation
Olsen et al. Increased frequency of intestinal CD4+ T cells reactive with mycobacteria in patients with Crohn's disease
CA2643158A1 (fr) Procedes pour le diagnostic et le pronostic de la reaction de greffe contre hote par la mesure de cellules cd3+cd4+cd8.beta.+ dans le sang peripherique
Korosec et al. Acetylsalicylic acid-triggered 15-HETE generation by peripheral leukocytes for identifying ASA sensitivity
Yavasoglu et al. Penile ulcer ATRA related in patient with acute promyelocytic leukemia
Jalalvand et al. Blood regulatory T cells in inflammatory bowel disease, a systematic review, and meta-analysis